Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of concurrent antiplatelet/NSAID use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDanny HillPWPhilip S. WellsMCMarc Carrier

Discussion

Loading...

Member takes

Overview

Post-hoc analysis reveals increased bleeding risk with antiplatelet/NSAID use in cancer patients on apixaban.

Key Points

  • Concurrent NSAID use raises the risk of clinically relevant bleeding in cancer patients on apixaban, with a hazard ratio of 1.78.
  • Among 574 patients in the AVERT trial, 557 were analyzed for antiplatelet or NSAID impacts on bleeding risks.
  • The study shows that antiplatelet use results in even higher rates of bleeding compared to those without, highlighting the significance of bleeding risks.
  • Findings support the need for individualized assessments of antiplatelet and NSAID use before thromboprophylaxis in cancer patients.

Cite This Study

Hill et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d31bhttps://doi.org/10.1182/blood-2025-741
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of apixaban 5 mg vs 2.5 mg for the prevention of cancer-associated venous thromboembolism: A pooled analysis of two studies2025
  2. 2Distribution and risk for bleeding in patients with cancer by anticoagulant therapy exposure2025
  3. 3Reduced‐Dose Versus Full‐Dose Direct Oral Anticoagulants for Extended Secondary Venous Thromboembolism Prophylaxis in Cancer Patients: A Systematic Review and Meta‐Analysis of Randomized Trials2025 · 3 citations
  4. 4Comparison of the Safety and Effectiveness of Apixaban Versus Rivaroxaban in Acute Venous Thromboembolism: A Propensity-Matched Real-World TriNetX Study with Obesity and Cancer Subgroup Analyses2026
  5. 5Implications of the API-CAT Trial for Extended Secondary Prophylaxis of Cancer-associated Venous Thromboembolism: Guidance from an Expert Panel.2025 · 3 citations